Replies to post #128687 on Biotech Values

[DewDiligence]

Re: Gilenya 5-year data

Seems like 50% of patients completing the 5 yr trial might be a bit low given the advantage of oral delivery. I wonder to what extent the discontinuations are due to side effects vs. medical community steering patients away until more data is collected.

50% is actually a good patient-continuation rate after five years for an open-label extension of a phase-2 trial.